[go: up one dir, main page]

CU20190073A7 - 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas - Google Patents

2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas

Info

Publication number
CU20190073A7
CU20190073A7 CU2019000073A CU20190073A CU20190073A7 CU 20190073 A7 CU20190073 A7 CU 20190073A7 CU 2019000073 A CU2019000073 A CU 2019000073A CU 20190073 A CU20190073 A CU 20190073A CU 20190073 A7 CU20190073 A7 CU 20190073A7
Authority
CU
Cuba
Prior art keywords
sup
compounds
dihydropyridazine
heteroaryl
oxo
Prior art date
Application number
CU2019000073A
Other languages
English (en)
Other versions
CU24564B1 (es
Inventor
Dr Benjamin Bader
Dr Rafael Carretero
Dr Llona Gutcher
Dr Horst Irlbacher
Dr Christina Kober
Prof Dr Michael Platten
Dr Ulrike Röhn
Dr Lars Röse
Dr Norbert Schmees
Dr Detlef Stöckigt
Dr Ludwing Zorn
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of CU20190073A7 publication Critical patent/CU20190073A7/es
Publication of CU24564B1 publication Critical patent/CU24564B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

<p>La presente invención comprende compuestos de 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamida de la fórmula general (I):</p> <p>ESPACIO PARA FÓRMULA</p> <p>en donde X, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> y R<sup>5</sup> son como se definen en la presente, procedimientos para preparar tales compuestos, compuestos intermedios útiles para preparar dichos compuestos, y combinaciones farmacéuticas que comprenden tales compuestos, los cuales son útiles para el tratamiento o la profilaxis de enfermedades, en particular cáncer o afecciones con respuestas inmunes desreguladas u otros trastornos asociados con la señalización anormal de AHR, como único agente o en combinación con otros ingredientes activos.</p>
CU2019000073A 2017-02-09 2018-02-02 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas CU24564B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17155406 2017-02-09
EP17202882 2017-11-21
PCT/EP2018/052627 WO2018146010A1 (en) 2017-02-09 2018-02-02 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer

Publications (2)

Publication Number Publication Date
CU20190073A7 true CU20190073A7 (es) 2020-03-04
CU24564B1 CU24564B1 (es) 2022-01-13

Family

ID=61188789

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000073A CU24564B1 (es) 2017-02-09 2018-02-02 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas

Country Status (38)

Country Link
US (2) US20240294505A1 (es)
EP (1) EP3580211B1 (es)
JP (1) JP7128826B2 (es)
KR (1) KR102627266B1 (es)
CN (3) CN116531380A (es)
AU (1) AU2018217860B2 (es)
BR (1) BR112019016497A2 (es)
CA (1) CA3052718A1 (es)
CL (1) CL2019002255A1 (es)
CO (1) CO2019008684A2 (es)
CR (1) CR20190364A (es)
CU (1) CU24564B1 (es)
CY (1) CY1124484T1 (es)
DK (1) DK3580211T3 (es)
DO (1) DOP2019000206A (es)
EC (1) ECSP19057713A (es)
ES (1) ES2847162T3 (es)
GE (1) GEP20217281B (es)
HR (1) HRP20210143T1 (es)
HU (1) HUE053191T2 (es)
IL (1) IL268469B (es)
JO (1) JOP20190193A1 (es)
LT (1) LT3580211T (es)
MA (1) MA47447B1 (es)
MX (1) MX2019009571A (es)
NI (1) NI201900085A (es)
PE (1) PE20191496A1 (es)
PH (1) PH12019501846A1 (es)
PL (1) PL3580211T3 (es)
RS (1) RS61401B1 (es)
SA (1) SA519402422B1 (es)
SG (1) SG11201907232XA (es)
SI (1) SI3580211T1 (es)
TW (1) TWI770113B (es)
UA (1) UA124507C2 (es)
UY (1) UY37606A (es)
WO (1) WO2018146010A1 (es)
ZA (1) ZA201905902B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190193A1 (ar) * 2017-02-09 2019-08-08 Bayer Pharma AG ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
CN109813913B (zh) * 2019-01-31 2021-11-09 中国医学科学院肿瘤医院 芳烃受体(AhR)在预测免疫治疗效果中的应用
EP3715471A1 (en) 2019-03-29 2020-09-30 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Ahr signature marker set
EP3721894A1 (en) 2019-04-10 2020-10-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof
CN112724256B (zh) * 2019-10-28 2022-09-16 中国农业大学 一种高稳定性的磺胺类药物抗体hAb 4D11及其应用
EP3835432A1 (en) 2019-12-10 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer
US20230084899A1 (en) * 2019-12-16 2023-03-16 Bayer Aktiengesellschaft Combination of an ahr-inhibitor and an pd1-inhibitor antibody and its use in the treatment of cancer
WO2021173082A1 (en) 2020-02-26 2021-09-02 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of ahr signalling
WO2021194326A1 (en) * 2020-03-27 2021-09-30 Dong-A St Co., Ltd. Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
CN114369097B (zh) * 2020-10-15 2023-07-14 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
CN114539221A (zh) * 2020-11-27 2022-05-27 苏州泽璟生物制药股份有限公司 氘代2-芳杂环-3-氧-2,3-二氢哒嗪-4-甲酰胺类抑制剂及其制备方法和应用
CN114685426A (zh) * 2020-12-28 2022-07-01 苏州泽璟生物制药股份有限公司 磺酰胺类抑制剂及其制备方法和应用
CN114835687B (zh) * 2021-04-02 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂
WO2023043753A1 (en) * 2021-09-14 2023-03-23 Allianthera (Suzhou) Biopharmaceutical Co., Ltd. 2-aryl or heteroaryl-3-oxo-4-carbamide-6-cyclic-dihydropyrazine aryl hydrocarbon receptor modulators and their use in the treatment of diseases and disorders
CA3235250A1 (en) 2021-10-20 2023-04-27 University Of Rochester Methods and compositions for rejuvenating cns glial populations by suppression of transcription factors
WO2024076300A1 (en) 2022-10-03 2024-04-11 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134467A1 (de) 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CA2340230C (en) * 1998-08-14 2008-03-11 Nihon Nohyaku Co., Ltd. Pyridazinone derivatives having cell adhesion inhibiting activity
JP2000119257A (ja) 1998-08-14 2000-04-25 Nippon Nohyaku Co Ltd ピリダジノン誘導体
JP4233868B2 (ja) 2000-09-18 2009-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピリダジノンおよびトリアジノン化合物類ならびにそれらの医薬用途
FR2847253B1 (fr) * 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
AR057986A1 (es) 2005-11-21 2008-01-09 Japan Tobacco Inc Compuesto heterociclico y su uso farmaceutico
EP2518063B1 (en) * 2006-12-21 2017-02-01 Sloan-Kettering Institute For Cancer Research Pyridazinones and furan-containing compounds
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CN107648216B (zh) 2010-07-27 2021-03-30 波士顿大学管理委员会 作为新型癌症疗法的芳烃受体(AhR)调节剂
US20170173008A1 (en) 2014-03-19 2017-06-22 President And Fellows Of Harvard College Antimicrobial agents and screening methods
US11040035B2 (en) 2016-05-25 2021-06-22 Bayer Pharma Aktiengesellschaft 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
JOP20190193A1 (ar) * 2017-02-09 2019-08-08 Bayer Pharma AG ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
US11459312B2 (en) 2017-11-21 2022-10-04 Bayer Aktiengesellschaft Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides

Also Published As

Publication number Publication date
WO2018146010A1 (en) 2018-08-16
CN110678459A (zh) 2020-01-10
SA519402422B1 (ar) 2021-11-14
CN110678459B (zh) 2023-04-04
US20230121195A1 (en) 2023-04-20
EP3580211A1 (en) 2019-12-18
PL3580211T3 (pl) 2021-04-19
SG11201907232XA (en) 2019-09-27
MX2019009571A (es) 2020-01-20
LT3580211T (lt) 2021-02-25
HRP20210143T1 (hr) 2021-03-19
JOP20190193A1 (ar) 2019-08-08
JP7128826B2 (ja) 2022-08-31
PH12019501846A1 (en) 2020-03-09
GEP20217281B (en) 2021-08-10
CL2019002255A1 (es) 2020-01-03
US11795164B2 (en) 2023-10-24
RS61401B1 (sr) 2021-02-26
HUE053191T2 (hu) 2021-06-28
CR20190364A (es) 2019-09-27
KR102627266B1 (ko) 2024-01-24
IL268469A (en) 2019-09-26
CN116531380A (zh) 2023-08-04
PE20191496A1 (es) 2019-10-21
US20240294505A1 (en) 2024-09-05
SI3580211T1 (sl) 2021-06-30
AU2018217860A1 (en) 2019-08-22
MA47447B1 (fr) 2021-02-26
NI201900085A (es) 2019-11-15
CY1124484T1 (el) 2022-07-22
DOP2019000206A (es) 2019-09-30
TW201840549A (zh) 2018-11-16
UY37606A (es) 2018-09-28
JP2020506946A (ja) 2020-03-05
KR20190115460A (ko) 2019-10-11
AU2018217860B2 (en) 2021-07-08
CU24564B1 (es) 2022-01-13
EP3580211B1 (en) 2020-12-02
CA3052718A1 (en) 2018-08-16
ECSP19057713A (es) 2019-08-30
ZA201905902B (en) 2021-05-26
CO2019008684A2 (es) 2019-08-20
ES2847162T3 (es) 2021-08-02
MA47447A (fr) 2019-12-18
CN116554152A (zh) 2023-08-08
DK3580211T3 (da) 2021-01-25
BR112019016497A2 (pt) 2022-05-10
UA124507C2 (uk) 2021-09-29
IL268469B (en) 2022-04-01
TWI770113B (zh) 2022-07-11

Similar Documents

Publication Publication Date Title
CU20190073A7 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
CU20180143A7 (es) 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
ECSP19030002A (es) 1,2,4-triazolonas 2,4,5-trisustituidas
CO2019007863A2 (es) Derivados de benzooxazol como inmunomoduladores
MX2018016273A (es) Compuestos heterociclicos como inmunomoduladores.
MX2018007774A (es) Compuestos heterociclicos como inmunomoduladores.
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
CO2021014008A2 (es) Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
CO2017011958A2 (es) Benzamidas sustituidas y métodos para utilizarlas
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
CO2022001257A2 (es) 1,2,4]triazolo[1,5-c]quinazolin-5-aminas
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CL2018001631A1 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
CL2019002583A1 (es) Inhibidores duales de magl y faah.
CL2022003703A1 (es) Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos
ECSP21062210A (es) Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias
AR117459A1 (es) Imidazopiridina y compuestos de imidazopiridazina y usos de los mismos